Back to Screener

Healthcare

Genscript Biotech Corporation(GNNSF)

Live Price

Offline

$1.60

+0.00% today

1Y Change

-27.27%

Window

Jun 26, 2025 โ†’ Jun 24, 2026

Market Cap
$3.83B
Revenue Growth
+61.6%
EPS Growth
-117.9%
Dividend Yield
0.0%

Coverage: 256 bars ยท Jun 26, 2025 โ†’ Jun 24, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Genscript Biotech Corporation (GNNSF) is a Healthcare stock with a market cap of $3.83B and listed on OTC. The stock last traded around $1.60 and down 27.3% across the available one-year price window (Jun 26, 2025 โ†’ Jun 24, 2026). Baseline metrics include revenue growth of +61.6%, EPS growth of -117.9%, a dividend yield of 0.0%. What stands out right now is revenue +61.6%, EPS -117.9%, free cash flow +434.4% with operating margin 26.6% and ROIC 5.6%. Valuation is more restrained than many high-expectation growth names at price/sales 4.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines GNNSF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Above sector median

+61.6% vs +7.6% peer median

Operating Margin

Above sector median

+26.6% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

The operating picture looks softer than before

Revenue is at +61.6% and EPS is at -117.9%, with operating margin around 26.6%.

Benchmark Edge

GNNSF vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

GNNSF

โ€”

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

GNNSF Max Drawdown

-46.28%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for GNNSF and SPY.

Calendar-year return history is still loading or unavailable.
Genscript Biotech Corporation logo

Company Overview

Genscript Biotech Corporation

Other OTC

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.

Leadership
Weihui Shao
IPO Date
Sep 28, 2017
Employees
5.6k
Street Address
Jiangning Science Park
Mailing
Nanjing, 211100
Region
Nanjing, CN
Reporting Currency
USD
Investor Line
86 25 5889 7288
Last Updated
Apr 29, 2026
ISIN: KYG3825B1059
Reports in USD

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
โ€”
EV/EBITDA
12.9
Price/Sales
4.0
Price/Book
1.0

Growth

Revenue
+61.6%
EPS
-117.9%
Free Cash Flow
+434.4%

Profitability

Gross Margin
57.6%
Operating Margin
26.6%
Net Margin
-55.6%
ROE
-12.7%
ROIC
5.6%

Balance Sheet

Debt/Equity
0.13
Current Ratio
1.47

Earnings Reports

No earnings data available

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.